HIMS vs AMGN Stock Comparison: AI Score, Valuation, Performance and Upside
HIMS and AMGN sit at opposite ends of healthcare. Hims & Hers is a fast-growing consumer subscription platform that distributes treatments and is exposed to marketing costs and regulatory rules. Amgen is a large, profitable biotechnology company with a diversified marketed portfolio, a dividend, meaningful debt, and pipeline outcomes that matter. Growth and optionality on one side; cash generation and income on the other.
Use this HIMS vs AMGN comparison to decide whether you are buying a consumer business that happens to sell healthcare or a drug company. Hims & Hers should be judged on subscriber economics and retention like a subscription business. Amgen should be judged on portfolio durability, biosimilar erosion, and pipeline value.
AMGN holds the edge across 4 of 5 key metrics in this comparison. AMGN leads on both 1-year return (+48.49%) and forward P/E quality (15.46x vs 29.03x for HIMS), a relatively favorable combination of momentum and valuation. On fundamentals, HIMS is growing revenue faster (38.20%), while AMGN maintains the higher operating margin (35.55%) — a classic growth-versus-profitability split. Analyst consensus implies meaningfully more upside for HIMS (+7.36%) than for AMGN (+2.83%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- Want higher-growth exposure to consumer healthcare delivery
- Believe telehealth subscriptions will continue taking share of routine prescriptions
- Accept regulatory and marketing cost risk as the primary threats
- Do not need dividend income from the position
- Want a large, profitable biotechnology company with diversified marketed products
- Value a long-standing dividend supported by strong free cash flow
- See rare disease assets as durable growth to offset biosimilar erosion
- Prefer lower volatility than a consumer growth stock
| Metric | HIMS | AMGN |
|---|---|---|
| AI scorei | 42.5 | 49.2 |
| AI ranki | #844 | #535 |
| Latest closei | $29.42 | $414.61 |
| 1M returni | -1.37% | -5.84% |
| 6M returni | +51.81% | +18.88% |
| 1Y returni | -46.38% | +48.49% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | HIMS | AMGN |
|---|---|---|
| 1Y ago | $5.36K (-46.4%) started 2025-09-25 | $15.29K (+52.9%) started 2025-09-25 |
| 5Y ago | $35.19K (+251.9%) started 2021-09-27 | $24.92K (+149.2%) started 2021-09-27 |
| 10Y ago | $30.02K (+200.2%) started 2019-09-13 | $41.89K (+318.9%) started 2016-09-26 |
Hypothetical — past performance does not guarantee future results.
| Metric | HIMS | AMGN |
|---|---|---|
| Market capi | $6.79B | $204.01B |
| Trailing P/Ei | N/A | 23.42 |
| Forward P/Ei | 29.03 | 15.46 |
| Price/Salesi | N/A | 4.57 |
| EV/Revenuei | 2.85 | 6.49 |
| Analyst targeti | $31.23 | $388.03 |
| Target upsidei | +7.36% | +2.83% |
| Metric | HIMS | AMGN |
|---|---|---|
| Revenue growthi | 38.20% | 9.50% |
| Earnings growthi | N/A | 64.90% |
| EPS growthi | N/A | +64.90% |
| FCF margini | +32.95% | +22.69% |
| Operating margini | -12.75% | 35.55% |
| Profit margini | -5.51% | 22.95% |
| ROIC proxyi | -32.03% | 91.47% |
| Return on equityi | -32.03% | 91.47% |
| Dividend yieldi | N/A | 2.64% |
| Payout ratioi | 0.00% | 60.87% |
| Dividend growth streaki | N/A | No increase yet |
| Betai | 2.42 | 0.43 |
| Debt/equityi | 477.13 | 490.28 |
| Current ratioi | 0.93 | 1.37 |
| Quick ratioi | 0.82 | 0.95 |
Over the past year, HIMS and AMGN have moved barely in the same direction (correlation of 0.07), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | HIMS | AMGN |
|---|---|---|---|
| 1Y | Growthi | -46.38% | +52.89% |
| CAGRi | -46.41% | +52.98% | |
| Volatilityi | 91.78% | 29.45% | |
| Sharpe ratioi | -0.29 | 1.44 | |
| Sortino ratioi | -0.45 | 2.31 | |
| Max drawdowni | 76.86% | 16.57% | |
| Current drawdowni | 53.12% | 6.64% | |
| Avg drawdowni | 49.38% | 5.72% | |
| Ulcer Indexi | 52.09% | 7.51% | |
| Max daily dropi | 16.03% | 10.08% | |
| Max wkly dropi | 32.71% | 15.03% | |
| 5Y | Growthi | +251.91% | +119.39% |
| CAGRi | +28.65% | +17.03% | |
| Volatilityi | 84.29% | 24.77% | |
| Sharpe ratioi | 0.66 | 0.58 | |
| Sortino ratioi | 1.03 | 0.87 | |
| Max drawdowni | 78.88% | 24.86% | |
| Current drawdowni | 57.20% | 6.64% | |
| Avg drawdowni | 32.28% | 8.15% | |
| Ulcer Indexi | 37.46% | 10.32% | |
| Max daily dropi | 34.63% | 10.08% | |
| Max wkly dropi | 39.06% | 15.03% | |
| 10Y | Growthi | +200.20% | +210.73% |
| CAGRi | +16.92% | +12.01% | |
| Volatilityi | 77.57% | 25.26% | |
| Sharpe ratioi | 0.53 | 0.40 | |
| Sortino ratioi | 0.82 | 0.59 | |
| Max drawdowni | 87.29% | 24.86% | |
| Current drawdowni | 57.20% | 6.64% | |
| Avg drawdowni | 43.70% | 8.20% | |
| Ulcer Indexi | 52.14% | 10.03% | |
| Max daily dropi | 34.63% | 10.08% | |
| Max wkly dropi | 39.06% | 15.79% |
| Category | HIMS | AMGN |
|---|---|---|
| Company | Hims & Hers Health, Inc. | Amgen Inc. |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - General |
| Core business | Direct-to-consumer telehealth subscription platform spanning sexual health, hair loss, dermatology, mental health, and weight management, pairing virtual clinical consultations with product fulfilment. | Large biotechnology company with a portfolio spanning cardiovascular, bone health, inflammation, oncology, and rare disease, expanded through the Horizon Therapeutics acquisition. Also operates a biosimilars business and is developing obesity candidates. |
| Investor focus | Subscriber additions and retention, weight-loss category composition, customer acquisition cost, and category gross margins. | Rare disease portfolio growth, biosimilar competition against mature products, obesity pipeline results, debt reduction after acquisition, and dividend coverage. |
- Recurring subscription revenue with improving economics as the customer base scales
- Strong consumer brand in categories where patients value privacy and convenience
- Fast growth from a relatively small revenue base
- Large, diversified marketed portfolio generating substantial free cash flow
- Rare disease assets from the Horizon acquisition provide durable, high-value growth
- Long-standing dividend with a record of increases
- Regulatory shifts around telehealth prescribing and compounded medications can change the offering overnight
- Dependent on paid marketing, so rising acquisition costs directly hit margins
- Does not own the underlying drugs it dispenses
- Several mature products face biosimilar and generic erosion
- Carries significant debt taken on for the Horizon acquisition
- Obesity pipeline results are a meaningful swing factor for sentiment
Compare more than two at a time
This page is a fixed writeup on HIMS and AMGN. Our comparison engine is the interactive version: load up to five tickers, switch timeframes, and get the correlation, drawdown, and overlap analysis that a static page can't show.
Add three more names beside HIMS and AMGN, mixing stocks and ETFs in the same table — useful when the real question is which of a whole peer group to own.
AI score, forward P/E, analyst target upside, operating margin, and revenue growth are scored head-to-head, with a running tally of which ticker leads on how many metrics.
Volatility, Sharpe and Sortino ratios, maximum, current, and average drawdown, Ulcer Index, and worst single-day and single-week drops across every timeframe.
Pairwise daily-return correlation for every combination, so you can see whether two holdings actually diversify each other or just move together.
A scatter plot of forward P/E against return on equity, plus drawdown and 30-day rolling volatility charts, to separate what is cheap from what is merely beaten down.
For ETFs, a top-holdings comparison that exposes hidden overlap between funds. Every comparison exports to CSV for your own spreadsheet work.
Two comparisons a week are free without an account. A 14-day trial removes the limit and adds AI price forecasts, stock rankings, saved watchlists, and the intrinsic value calculator — no credit card required.
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Full valuation workup with AI Score, Monte Carlo forecast, and bull/bear case — free preview, premium data from $3.99.